Models
Source: Visible Alpha consensus via S&P Xpressfeed · Consensus as of 2026-07-15 · generated 2026-07-20.
Model trust
This is a deep, timely consensus rather than a thin or stale one.
Base currency: USD · VA scales normalized from Abs, M; item currencies and units retained · Coverage depth and vintage; broker count is the maximum represented.
| Brokers | Line items | Last revision |
|---|---|---|
| 13 | 537 | 2026-07-15 |
Operating KPIs
Base currency: USD · VA scales normalized from Abs, M; item currencies and units retained · FY-1A / FY0E / FY+1E; broker count shown per KPI.
| Operating KPI | Source | FY-1A | FY0E | FY+1E | Brokers |
|---|---|---|---|---|---|
| Companion animal - YoY growth(%) | CD | 5.3% | 1.6% | 4.1% | 13 |
| Contract manufacturing & human health | CD | 107,996.85bn Amount | 112,488.82bn Amount | 116,397.98bn Amount | 13 |
| Cost of sales - operating | CD | 2,668,178.87bn Amount | 2,767,306.78bn Amount | 2,869,954.01bn Amount | 13 |
| Income tax expense/(benefits) - operating | CD | 719,041.77bn Amount | 741,348.06bn Amount | 778,072.18bn Amount | 13 |
| Interest income/(expense) - operating | CD | -183,998.37bn Amount | -202,324.14bn Amount | -209,127.68bn Amount | 13 |
| Livestock | CD | 2,725,819.75bn Amount | 2,951,588.21bn Amount | 3,058,744.96bn Amount | 13 |
| Livestock - YoY growth(%) | CD | -5.9% | 8.0% | 3.6% | 13 |
| Amortization of intangible assets - operating | CD | 20,788.99bn Amount | 18,131.56bn Amount | 22,768.27bn Amount | 12 |
| Companion animal | CD | 6,611,907.33bn Amount | 6,671,153.91bn Amount | 6,946,724.56bn Amount | 12 |
| Companion animal - International | CD | 2,367,700.28bn Amount | 2,561,690.21bn Amount | 2,698,203.96bn Amount | 11 |
| Companion animal - US | CD | 4,241,105.20bn Amount | 4,108,771.72bn Amount | 4,235,834.60bn Amount | 11 |
| Contract manufacturing & human health - YoY growth(%) | CD | 34.9% | -3.7% | 3.3% | 11 |
P&L bridge
Base currency: USD · VA scales normalized from Abs, M; item currencies and units retained · Margins are derived against revenue; YoY compares adjacent fiscal columns; broker count shown per line.
| P&L line | FY-1A | FY0E | FY+1E | Brokers |
|---|---|---|---|---|
| Revenue | 9,445,708.94bn Amount | 9,735,230.93bn Amount (3.1% YoY) | 10,121,867.50bn Amount (4.0% YoY) | 13 |
| Gross Profit | 6,777,739.09bn Amount (71.8% margin) | 6,967,924.16bn Amount (71.6% margin; 2.8% YoY) | 7,251,913.49bn Amount (71.6% margin; 4.1% YoY) | 13 |
| Ebitda | 3,997,187.45bn Amount (42.3% margin) | 4,324,594.96bn Amount (44.4% margin; 8.2% YoY) | 4,519,539.86bn Amount (44.7% margin; 4.5% YoY) | 11 |
| Operating Income | 3,719,271.31bn Amount (39.4% margin) | 3,822,536.94bn Amount (39.3% margin; 2.8% YoY) | 4,000,793.86bn Amount (39.5% margin; 4.7% YoY) | 13 |
| Net Income | 2,818,513.62bn Amount (29.8% margin) | 2,882,780.85bn Amount (29.6% margin; 2.3% YoY) | 3,016,504.24bn Amount (29.8% margin; 4.6% YoY) | 13 |
| Eps | 6.34 Amount | 6.88 Amount (8.6% YoY) | 7.33 Amount (6.5% YoY) | 13 |
Consensus dispersion
Trio) spans roughly $1.6B to $2.0B, signaling an unsettled debate on the US companion-animal growth trajectory. The widest percentage spread is in the small contract manufacturing & human health line, where the dollar stakes are minor.
Base currency: USD · VA scales normalized from Abs, M; item currencies and units retained · Top high-low spreads relative to absolute mean; requires at least 3 brokers.
| Line item | Period | Mean | Min | Q1 | Q3 | Max | Spread / mean | Brokers |
|---|---|---|---|---|---|---|---|---|
| Contract manufacturing & human health - YoY growth(%) | 2QFY-2026 | 2.4% | -17.0% | 0.2% | 4.9% | 20.0% | 1555.3% | 10 |
| Companion animal - YoY growth(%) | 2QFY-2026 | -0.5% | -4.6% | -1.3% | 0.2% | 3.0% | 1425.6% | 12 |
| Contract manufacturing & human health - YoY growth(%) | 1QFY-2026 | 2.5% | -13.8% | 0.0% | 5.0% | 20.0% | 1375.6% | 11 |
| Contract manufacturing & human health - YoY growth(%) | FY-2026 | -3.7% | -9.8% | -6.0% | -2.4% | 9.5% | 522.8% | 11 |
| Livestock - YoY growth(%) | 4QFY-2025 | -1.4% | -5.4% | -2.7% | 0.2% | 1.0% | 471.4% | 11 |
| Contract manufacturing & human health - YoY growth(%) | 3QFY-2026 | 4.3% | 0.0% | 1.2% | 4.8% | 20.0% | 467.0% | 10 |
Quarterly path
Base currency: USD · VA scales normalized from Abs, M; item currencies and units retained · Next four supplied quarters; final column is maximum broker coverage in the row.
| Quarter | Companion animal - YoY growth(%) | Contract manufacturing & human health | Cost of sales - operating | Income tax expense/(benefits) - operating | Interest income/(expense) - operating | Total revenue | EPS Diluted, Applicable to common stockholders($) | Broker coverage |
|---|---|---|---|---|---|---|---|---|
| 3QFY-2026 | 3.1% | 23,781.01bn Amount | 712,999.64bn Amount | 197,684.05bn Amount | -53,812.78bn Amount | 2,502,429.87bn Amount | 1.86 Amount | 12 |
| 4QFY-2026 | 4.8% | 31,026.01bn Amount | 736,214.01bn Amount | 173,596.65bn Amount | -52,669.35bn Amount | 2,461,635.22bn Amount | 1.63 Amount | 12 |
| 1QFY-2027 | 4.4% | 23,651.86bn Amount | 661,524.72bn Amount | 174,757.02bn Amount | -54,757.58bn Amount | 2,348,038.42bn Amount | 1.62 Amount | 8 |
| 2QFY-2027 | 4.4% | 35,162.09bn Amount | 700,177.19bn Amount | 211,510.70bn Amount | -52,927.24bn Amount | 2,595,734.38bn Amount | 1.97 Amount | 8 |
80 stale period values omitted; 9 line items fully removed.